Cantabell (amlodipine/candesartan cilexetil) / Chong Kun Dang - LARVOL DELTA

Pharmacokinetic Comparison of a Fixed-Dose Combination of Candesartan Cilexetil/Amlodipine/Atorvastatin Versus Co-administration of Individual Formulations in Healthy Participants. (PubMed, Adv Ther) - P1 | "The Cmax and AUClast values of candesartan cilexetil/amlodipine/atorvastatin 16/10/40 mg and 16/5/20 mg, respectively, were within the BE ranges. There were no clinically significant differences in safety between the two formulations."

Journal • PK/PD data • Cardiovascular

A Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics of CKD-333 or Co-administration of CKD-333 and D085 in Healthy Volunteers (clinicaltrials.gov) - P1; N=51; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial • Cardiovascular

Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers (clinicaltrials.gov) - P1; N=51; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial • Cardiovascular

Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers (clinicaltrials.gov) - P1; N=51; Not yet recruiting; Sponsor: Chong Kun Dang Pharmaceutical

Clinical • New P1 trial • Cardiovascular

Clinical Study to Investigate the Pharmacokinetic Profiles and Safety of CKD-333 in Healthy Volunteers (clinicaltrials.gov) - P1; N=24; Completed; Sponsor: Chong Kun Dang Pharmaceutical; Not yet recruiting ➔ Completed

Trial completion